New oral anticoagulants and the risk of intracranial hemorrhage: Traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation

JAMA Neurology

Volumn 70, Issue 12, 2013, Pages 1486-1490

  Chatterjee, Saurav ^a   Sardar, Partha ^b   Biondi Zoccai, Giuseppe ^c   Kumbhani, Dharam J ^d  

^a BROWN UNIVERSITY   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN ETEXILATE; RIVAROXABAN; WARFARIN;

ARTICLE; BAYES THEOREM; BRAIN HEMORRHAGE; DRUG EFFICACY; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; META ANALYSIS; MONTE CARLO METHOD; PRIORITY JOURNAL; PROBABILITY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SYSTEMATIC REVIEW;

EID: 84890359770     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.4021     Document Type: Article

References (13)

1. Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke. 2012;43(6):1511-1517.
2. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared withwarfarin in older and younger patientswith atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363-2372.
3. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran vs warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
4. Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban vswarfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891.
5. Granger CB, Alexander JH, McMurray JJ, et al; ARISTOTLE Committees and Investigators. Apixaban vs warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992.
6. Hori M, Matsumoto M, Tanahashi N, et al; J-ROCKET AF Study Investigators. Rivaroxaban vs warfarin in Japanese patientswith atrial fibrillation: the J-ROCKET AF study. Circ J. 2012;76(9):2104-2111.
7. Ogawa S, Shinohara Y, Kanmuri K. Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation: the ARISTOTLE-J study. Circ J. 2011;75(8):1852-1859.
8. Connolly SJ, Eikelboom J, Joyner C, et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-817.
9. Higgins JPT, Altman DG, Sterne JAC. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 (Updated March 2011). http://handbook.cochrane. org. Accessed May 22, 2013.
10. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65-W94.
11. Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation. 2012;126(20):2381-2391.
12. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) vs warfarin in patients with atrial fibrillation. Am J Cardiol. 2012;110(3):453-460.
13. Lip GY, Larsen TB, Skjøth F, Rasmussen LH. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2012;60(8):738-746.